Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nina R Goldman

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Annals of the American Thoracic Society|February 26, 2021
Ratio of Oxygen Saturation Index to Guide Management of COVID-19 PneumoniaDouglas L Fink, Nina R Goldman, James Cai, et al.
Frontiers in Immunology|February 2, 2023
Dysregulated B cell function and disease pathogenesis in systemic sclerosisClaire F Beesley, Nina R Goldman, Taher E Taher, et al.
Rheumatology (Oxford, England)|January 3, 2025
Tocilizumab and rituximab for systemic sclerosis interstitial lung disease: a real-world cohort analysisNina R Goldman, Svetlana I Nihtyanova, Claire F Beesley, et al.
Respiratory Medicine|November 8, 2016
Patient eligibility for anti-fibrotic therapy in idiopathic pulmonary fibrosis can be altered by use of different sets of reference values for calculation of FVC percent predictedKatie Ward, Lydia Spurr, Nina R Goldman, et al.
Clinical and Experimental Rheumatology|February 27, 2026
Nintedanib in systemic sclerosis-associated interstitial lung disease: real-world cohort study on tolerability and discontinuationPunchalee Kaenmuang, Nina R Goldman, Arthihai Srirangan, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Annals of the American Thoracic Society|February 26, 2021
Ratio of Oxygen Saturation Index to Guide Management of COVID-19 PneumoniaDouglas L Fink, Nina R Goldman, James Cai, et al.
Frontiers in Immunology|February 2, 2023
Dysregulated B cell function and disease pathogenesis in systemic sclerosisClaire F Beesley, Nina R Goldman, Taher E Taher, et al.
Rheumatology (Oxford, England)|January 3, 2025
Tocilizumab and rituximab for systemic sclerosis interstitial lung disease: a real-world cohort analysisNina R Goldman, Svetlana I Nihtyanova, Claire F Beesley, et al.
Respiratory Medicine|November 8, 2016
Patient eligibility for anti-fibrotic therapy in idiopathic pulmonary fibrosis can be altered by use of different sets of reference values for calculation of FVC percent predictedKatie Ward, Lydia Spurr, Nina R Goldman, et al.
Clinical and Experimental Rheumatology|February 27, 2026
Nintedanib in systemic sclerosis-associated interstitial lung disease: real-world cohort study on tolerability and discontinuationPunchalee Kaenmuang, Nina R Goldman, Arthihai Srirangan, et al.
Pageof 1